

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4415771

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
PURDUE PHARMA L.P.	10/28/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	PURDUE PHARMACEUTICAL PRODUCTS L.P.
<b>Street Address:</b>	ONE STAMFORD FORUM
<b>Internal Address:</b>	201 TRESSER BOULEVARD
<b>City:</b>	STAMFORD
<b>State/Country:</b>	CONNECTICUT
<b>Postal Code:</b>	06901
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15314172
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6174496500
<b>Email:</b>	eshea@mccarter.com
<b>Correspondent Name:</b>	MCCARTER & ENGLISH, LLP
<b>Address Line 1:</b>	265 FRANKLIN STREET
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	123088-01101
<b>NAME OF SUBMITTER:</b>	WEI SONG
<b>SIGNATURE:</b>	/Wei Song/
<b>DATE SIGNED:</b>	05/16/2017
<b>Total Attachments: 5</b>	
source=7.01101 Executed Assignment Purdue Pharma to Purdue Pharmaceutical Products LP (2)#page1.tif	
source=7.01101 Executed Assignment Purdue Pharma to Purdue Pharmaceutical Products LP (2)#page2.tif	
source=7.01101 Executed Assignment Purdue Pharma to Purdue Pharmaceutical Products LP (2)#page3.tif	
source=7.01101 Executed Assignment Purdue Pharma to Purdue Pharmaceutical Products LP (2)#page4.tif	
source=7.01101 Executed Assignment Purdue Pharma to Purdue Pharmaceutical Products LP (2)#page5.tif	

**(1) PURDUE PHARMA L.P.**

**- and -**

**(2) PURDUE PHARMACEUTICAL PRODUCTS L.P.**

---

**ASSIGNMENT OF PATENT APPLICATIONS AND  
RELATED RIGHTS IN US**

---

THIS DEED OF ASSIGNMENT is made the 28 day of October 2016

**BETWEEN**

(1) **Purdue Pharma L.P.**, a limited partnership incorporated in Delaware whose principal place of business is at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901, USA (the "Assignor").

(2) **Purdue Pharmaceutical Products L.P.**, a limited partnership incorporated in Delaware whose principal place of business is at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901, USA (the "Assignee"); and

**BACKGROUND**

(A) The Assignor owns and is the applicant for certain patent applications ("the Applications") in respect of the Inventions respectively disclosed in the Applications ("the Inventions").

(B) The Assignor has agreed to assign to the Assignee the Inventions in the US and the US designations of the Applications as detailed in the Schedule ("the Assigned Applications") and all its rights, title and interest therein upon the terms and conditions set out below

**OPERATIVE PROVISIONS**

1. In consideration of the sum of £1 paid by the Assignee to the Assignor (the receipt and sufficiency of which the Assignor hereby acknowledges) the Assignor with full title guarantee **HEREBY ASSIGNS** to the Assignee:

(a) in respect of the US ("the Territory") only, the Inventions and the full and exclusive benefit of them;

- (b) all the rights of the Assignor in and to the Assigned Applications and the full and exclusive benefit of them and all rights privileges and advantages associated with them;
- (c) the full right to apply for and obtain patents or other similar forms of protection in respect of the Inventions in the Territory;
- (d) the right to make any new application or applications in the Territory in respect of any part or parts of the subject matter of any application or specification filed in connection with the Inventions;
- (e) any patents or other similar forms of protection granted in the Territory in respect of the Inventions pursuant to the Assigned Applications;
- (f) the right to claim priority of the Assigned Applications; and
- (g) the right to bring proceedings (anywhere in the world) for the recovery of damages and/or other remedies in respect of any previous infringement of the rights assigned by this Assignment.

TO HOLD the same unto the Assignee absolutely.

2. The Assignor hereby covenants with the Assignee that it shall execute such further documents and do such further acts, and shall procure on the part of the inventors of the Inventions the execution and doing of all such further documents and acts, as may reasonably be required by the Assignee to enable the Assignee (or its nominee) to enjoy the full benefit of the property and rights hereby assigned and to apply for any patents or other forms of protection in respect of the Inventions in the Territory, and fully and effectively to vest the same in the Assignee or as the Assignee shall direct.
3. The Assignor further covenants with the Assignee that at the request and expense of the Assignee it shall provide all such assistance as the Assignee may reasonably require in connection with any proceedings concerning the Assigned Applications or any patents, patent applications or similar rights applied for or arising in respect of the

Inventions in the Territory, including the disclosure of relevant documents and materials and the provision of oral and written testimony from relevant personnel.

4. This Assignment shall be governed by and construed in accordance with English law and shall be subject to the exclusive jurisdiction of the English courts.

IN WITNESS of which this Assignment has been executed as a Deed and delivered the date and year first above written.

#### SCHEDULE


##### Patent Applications

Reference	Application Number	Date Filed	Subject Matter	Designated States (PCT)
PC927305 P1283/WO	PCT/EP2015/061571	26-5-2015	Combination of EDO-S101 and proteasome inhibitor.	US only
PC927328 P1284/WO	PCT/EP2015/061572	26-5-2015	Combination of EDO-S101 and glucocorticoid.	US only
PC927331 P1285/WO	PCT/EP2015/061569	26-5-2015	Combination of EDO-S101 and class III receptor tyrosine kinase inhibitor.	US only
PC927678 P1328/WO	PCT/EP2015/056667	26-3-2015	Use of EDO-S101 in the treatment of brain cancer.	US only


SIGNED as a deed by  
PURDUE PHARMACEUTICAL PRODUCTS L.P.  
acting by **Stuart D. Baker**, Executive Vice President of Purdue Pharmaceutical Products Inc.,  
the general partner of Purdue Pharmaceutical Products L.P.:

Signature:  Date .....


in the presence of:

Signature of witness:  Date .....  
Name of witness: *Anthony Rancazio*  
Address of witness: *1301 Avenue of the Americas, NY 10019*  
Occupation of witness: *Lawyer*

SIGNED as a deed by  
PURDUE PHARMA L.P.  
acting by **Stuart D. Baker**, Executive Vice President of Purdue Pharmaceutical Products Inc.,  
the general partner of Purdue Pharmaceutical Products L.P.:

Signature:  Date .....

in the presence of:

Signature of witness:  Date .....  
Name of witness: *Anthony Rancazio*  
Address of witness: *1301 Avenue of the Americas NY 10019*  
Occupation of witness: *Lawyer*